The Interplay of Lung Cancer, COVID-19, and Vaccines.
Dragan TrivanovićŽeljka PeršurićAndrea AgajMarko JakopovicMiroslav SamaržijaLela BitarKrešimir PavelićPublished in: International journal of molecular sciences (2022)
Patients with cancer are more susceptible to a higher risk of coronavirus infection and its severe complications than the general population. In addition, these patients were not included in the pivotal clinical trials for COVID-19 vaccines. Therefore, considerable uncertainty remains regarding the management of cancer patients during the COVID-19 pandemic and the safety of COVID-19 vaccinations in cancer patients. In this review, we summarize the current knowledge generated from the beginning of the COVID-19 pandemic on the vulnerability of cancer patients to the coronavirus disease, as well as the effectiveness of COVID-19 vaccines in this population. We also discuss the available data on the effects of anticancer treatment with immune checkpoint inhibitors on the immune responses to SARS-CoV-2 in cancer patients. Special attention in this review will be given to patients with lung cancer, as such patients are at an increased risk for severe effects from COVID-19.
Keyphrases
- sars cov
- coronavirus disease
- respiratory syndrome coronavirus
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- immune response
- healthcare
- prognostic factors
- systematic review
- early onset
- randomized controlled trial
- machine learning
- climate change
- toll like receptor
- patient reported
- drug induced
- smoking cessation